HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Annexin XI is associated with cisplatin resistance and related to tumor recurrence in ovarian cancer patients.

AbstractPURPOSE:
Ovarian cancer patients treated with cisplatin-based chemotherapy often develop acquired cisplatin resistance and, consequently, cancer recurrence. The precise nature of chemoresistance remains unclear. In this study, a protein identified to be associated with cisplatin resistance in ovarian cancer cells was investigated in ovarian cancer tissues to address its clinical significance.
EXPERIMENTAL DESIGN:
Antibody microarrays were used to identify proteins consistently differentially expressed across three pairs of cisplatin-sensitive and cisplatin-resistant ovarian cancer cell lines. Immunoblotting was used to confirm observed alteration of protein expression. The protein expression was further evaluated by immunohistochemical staining using tissue microarrays containing various human normal and malignant tissues and 164 surgical specimens derived from primary and recurrent ovarian cancer patients who underwent primary debulking surgery followed by standard chemotherapeutic regimen.
RESULTS:
Annexin XI was down-regulated in all three cisplatin-resistant cell lines as compared with their parent cells. Annexin XI expression was observed in the majority of human normal organs and decreased in some of the most common human malignancies. The expression level of Annexin XI in first recurrent ovarian cancers was much lower than that in primary ovarian cancers (P = 0.0004). Increased Annexin XI immunoreactivity in ovarian cancers seemed to prolong the disease-free interval of patients (P = 0.03). Annexin XI immunoreactivity inversely correlated with in vitro cisplatin resistance in ovarian cancers (P = 0.01).
CONCLUSION:
Decreased expression of Annexin XI is characteristic for cisplatin-resistant cancer cells and may contribute to tumor recurrence. Annexin XI may be a potential marker for chemoresistance and earlier recurrence of ovarian cancer patients.
AuthorsJin Song, Ie-ming Shih, Ritu Salani, Daniel W Chan, Zhen Zhang
JournalClinical cancer research : an official journal of the American Association for Cancer Research (Clin Cancer Res) Vol. 13 Issue 22 Pt 1 Pg. 6842-9 (Nov 15 2007) ISSN: 1078-0432 [Print] United States
PMID17982121 (Publication Type: Journal Article, Research Support, N.I.H., Extramural, Research Support, U.S. Gov't, Non-P.H.S.)
Chemical References
  • Annexins
  • Antineoplastic Agents
  • Cisplatin
Topics
  • Adult
  • Aged
  • Aged, 80 and over
  • Annexins (analysis, metabolism)
  • Antineoplastic Agents (pharmacology)
  • Cell Line, Tumor
  • Cisplatin (pharmacology)
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Middle Aged
  • Neoplasm Recurrence, Local (metabolism)
  • Ovarian Neoplasms (metabolism, pathology)
  • Prognosis

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: